drugset / Trial / NCT04390945
Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer
Phase 2
Unknown
62 enrolled
The First Affiliated Hospital of Henan University of Science and Technology
NaSingle-groupOpen-labelTreatment
Summary
China is a country with a large incidence of esophageal cancer. The prevalence and mortality rate of esophageal cancer in China ranks fifth in the world. However, due to China's huge population base, new patients with esophageal cancer and deaths account for about 55% of the world. This study aimed to explore the efficacy and safety of Camrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Treatment of Patients With Local Recurrence of Esophageal Cancer.
Timeline
- Start
- 2021-12-01
- Primary completion
- 2023-10
- Completion
- 2024-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Background | Capecitabine | Small molecule | 625 mg/m2 | Oral |